Inhibrx Biosciences Stock Performance
| INBX Stock | USD 77.00 1.64 2.09% |
The company retains a Market Volatility (i.e., Beta) of 0.55, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Inhibrx Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Inhibrx Biosciences is expected to be smaller as well. At this point, Inhibrx Biosciences has a negative expected return of -0.015%. Please make sure to check out Inhibrx Biosciences' potential upside, and the relationship between the total risk alpha and kurtosis , to decide if Inhibrx Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Inhibrx Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental drivers, Inhibrx Biosciences is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (3.01) | Five Day Return 4.85 | Year To Date Return 4.8 | Ten Year Return 281.19 | All Time Return 281.19 |
1 | Mark Asset Management LP Buys Shares of 17,000 Inhibrx Biosciences, Inc. INBX - MarketBeat | 12/12/2025 |
2 | Inhibrx Assessing a Lofty Valuation After Fresh INBRX-106 and Ozekibart Milestone Updates | 12/18/2025 |
3 | Inhibrx Biosciences Shares Up 6.6 percent Time to Buy | 12/19/2025 |
4 | Inhibrx Biosciences Shares Down 7.9 percent - Heres Why - MarketBeat | 12/23/2025 |
5 | Is Inhibrx Biosciences Inc. stock dividend yield sustainable - 2025 Biggest Moves High Conviction Trade Alerts - ulpravda.ru | 01/08/2026 |
6 | Inhibrx Biosciences Reports Promising Q3 2025 Results - MSN | 01/26/2026 |
7 | Inhibrx Biosciences Stock Price Up 10.2 percent - Still a Buy - MarketBeat | 02/02/2026 |
8 | Disposition of 32431 shares by Deck Kelly of Inhibrx Biosciences at 11.25 subject to Rule 16b-3 | 02/13/2026 |
| Begin Period Cash Flow | 277.9 M | |
| Total Cashflows From Investing Activities | -2.6 M |
Inhibrx Biosciences Relative Risk vs. Return Landscape
If you would invest 8,268 in Inhibrx Biosciences on November 25, 2025 and sell it today you would lose (404.00) from holding Inhibrx Biosciences or give up 4.89% of portfolio value over 90 days. Inhibrx Biosciences is currently does not generate positive expected returns and assumes 3.7125% risk (volatility on return distribution) over the 90 days horizon. In different words, 33% of stocks are less volatile than Inhibrx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Inhibrx Biosciences Target Price Odds to finish over Current Price
The tendency of Inhibrx Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 77.00 | 90 days | 77.00 | about 72.98 |
Based on a normal probability distribution, the odds of Inhibrx Biosciences to move above the current price in 90 days from now is about 72.98 (This Inhibrx Biosciences probability density function shows the probability of Inhibrx Stock to fall within a particular range of prices over 90 days) .
Inhibrx Biosciences Price Density |
| Price |
Predictive Modules for Inhibrx Biosciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Inhibrx Biosciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Inhibrx Biosciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Inhibrx Biosciences is not an exception. The market had few large corrections towards the Inhibrx Biosciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Inhibrx Biosciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Inhibrx Biosciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.01 | |
β | Beta against Dow Jones | 0.55 | |
σ | Overall volatility | 4.77 | |
Ir | Information ratio | -0.0056 |
Inhibrx Biosciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Inhibrx Biosciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Inhibrx Biosciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Inhibrx Biosciences generated a negative expected return over the last 90 days | |
| Inhibrx Biosciences has high historical volatility and very poor performance | |
| Inhibrx Biosciences currently holds about 176.38 M in cash with (194.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52. | |
| Inhibrx Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Inhibrx Biosciences Stock Price Up 10.2 percent - Still a Buy - MarketBeat |
Inhibrx Biosciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Inhibrx Stock often depends not only on the future outlook of the current and potential Inhibrx Biosciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Inhibrx Biosciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 14.5 M | |
| Cash And Short Term Investments | 152.6 M |
Inhibrx Biosciences Fundamentals Growth
Inhibrx Stock prices reflect investors' perceptions of the future prospects and financial health of Inhibrx Biosciences, and Inhibrx Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Inhibrx Stock performance.
| Return On Equity | -1.14 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (21.07) % | ||||
| Current Valuation | 428.15 M | ||||
| Shares Outstanding | 14.49 M | ||||
| Price To Book | 7.41 X | ||||
| Price To Sales | 347.75 X | ||||
| Revenue | 200 K | ||||
| Gross Profit | (171.77 M) | ||||
| EBITDA | 1.7 B | ||||
| Net Income | 1.69 B | ||||
| Cash And Equivalents | 176.38 M | ||||
| Cash Per Share | 4.52 X | ||||
| Total Debt | 8.05 M | ||||
| Debt To Equity | 4.22 % | ||||
| Current Ratio | 7.51 X | ||||
| Book Value Per Share | 4.74 X | ||||
| Cash Flow From Operations | (194.41 M) | ||||
| Earnings Per Share | (16.57) X | ||||
| Market Capitalization | 486.86 M | ||||
| Total Asset | 180.77 M | ||||
| Retained Earnings | (106.13 M) | ||||
| Working Capital | 119.67 M | ||||
About Inhibrx Biosciences Performance
Evaluating Inhibrx Biosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Inhibrx Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Inhibrx Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (137.11) | (143.96) | |
| Return On Tangible Assets | 8.40 | 8.82 | |
| Return On Capital Employed | (2.72) | (2.59) | |
| Return On Assets | 8.40 | 8.82 | |
| Return On Equity | 11.37 | 11.94 |
Things to note about Inhibrx Biosciences performance evaluation
Checking the ongoing alerts about Inhibrx Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Inhibrx Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Inhibrx Biosciences generated a negative expected return over the last 90 days | |
| Inhibrx Biosciences has high historical volatility and very poor performance | |
| Inhibrx Biosciences currently holds about 176.38 M in cash with (194.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52. | |
| Inhibrx Biosciences has a poor financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Inhibrx Biosciences Stock Price Up 10.2 percent - Still a Buy - MarketBeat |
- Analyzing Inhibrx Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Inhibrx Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Inhibrx Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Inhibrx Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Inhibrx Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Inhibrx Biosciences' stock. These opinions can provide insight into Inhibrx Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Inhibrx Stock Analysis
When running Inhibrx Biosciences' price analysis, check to measure Inhibrx Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx Biosciences is operating at the current time. Most of Inhibrx Biosciences' value examination focuses on studying past and present price action to predict the probability of Inhibrx Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx Biosciences' price. Additionally, you may evaluate how the addition of Inhibrx Biosciences to your portfolios can decrease your overall portfolio volatility.